🔴 LIVE: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

BRIEF-Acasti Pharma Reports Last Patient Visit In Trilogy 1 Phase 3 Trial Of Capre For The Treatment Of Severe Hypertriglyceridemia

Published 2019-11-26, 08:01 a/m
© Reuters.  BRIEF-Acasti Pharma Reports Last Patient Visit In Trilogy 1 Phase 3 Trial Of Capre For The Treatment Of Severe Hypertriglyceridemia
ACST
-

Nov 26 (Reuters) - Acasti Pharma Inc ACST.V :

* ACASTI PHARMA REPORTS LAST PATIENT VISIT IN TRILOGY 1 PHASE 3 TRIAL OF CAPRE FOR THE TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA

* ACASTI PHARMA - EXPECTS LAST PATIENT TO COMPLETE FINAL VISIT IN TRILOGY 2 IN EARLY JAN 2020, WITH TOPLINE RESULTS EXPECTED TOWARDS END OF JAN 2020

* ACASTI PHARMA - IF TRILOGY 1, TRILOGY 2 RESULTS ARE POSITIVE, CO INTENDS TO FILE AN NDA BY MID-2020 TO OBTAIN REGULATORY APPROVAL FOR CAPRE IN U.S.

* ACASTI PHARMA INC - ON TRACK TO REPORT TOPLINE RESULTS FOR TRILOGY 1 IN DEC 2019 AND TRILOGY 2 IN JAN 2020

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.